Our Thesis Plays Out as GE Sells BioPharma to Danaher
We're still evaluating the deal, but we don't expect a change to GE's fair value estimate.
On Feb. 25, narrow-moat-rated General Electric (GE) announced it has agreed to sell its BioPharma business to Danaher (DHR) for approximately $21.4 billion, including $21 billion cash and assumption of certain pension liabilities (about 17 times forward EBITDA). We had speculated that this deal was possible as early as last year and wrote that the deal would be "approximately $20 billion at current forward enterprise value/EBITDA multiples." The GE Life Sciences unit will join Danaher’s Life Sciences as a stand-alone business. Pharmaceutical Diagnostics, which currently forms part of GE Life Sciences, will stay with the remainder of GE Healthcare. That business supplies contrast media and molecular imaging consumables for radiology customers. This carve-out clearly makes sense to us, given the synergies with the remaining GE Healthcare’s core medical imaging business. While we’re still evaluating the full impact of this transaction, mostly as to timing, we’re not overly surprised by the deal and don’t expect to materially change our GE fair value estimate of $13.80 per share.
Danaher had expressed interest in this business as early as the spring of 2018, as reported by The Wall Street Journal. At the time, however, GE was reportedly not interested in pursuing a deal. While GE is losing one of its bright stars that typically increases its top line at a high-single-digit year-over-year clip, we think CEO Larry Culp is making the right strategic decision. First, while this deal may make the GE Healthcare initial public offering slightly less attractive, life science valuations are currently high, and this deal offers Culp and his team the opportunity to deleverage the balance sheet. Second, we believe GE Life Sciences has little strategic value to GE’s future as an industrial infrastructure business.
|Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.|
Joshua Aguilar does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.